REACT - REAl Care for AsThma - A Disease Study to Identify Patients With Severe Uncontrolled Asthma
Reason given: The early termination of the study is due to challenging recruitment of study sites and patients.
Key facts
- Where
- Berlin, Blankenhein, Bonn, Fürstenwalde, Gauting, and Weißenburg, GermanySee the 6 sites
Where in Germany
- BerlinBerlin, GermanyNo longer taking part
- BlankenheinBlankenhein, GermanyNo longer taking part
- BonnBonn, GermanyNo longer taking part
- FürstenwaldeFürstenwalde, GermanyNo longer taking part
- GautingGauting, GermanyNo longer taking part
- WeißenburgWeißenburg, GermanyNo longer taking part
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT06299306
- Record updated
- 18 September 2025
- Original description
This is a multi-center, single-country, single-arm, prospective, disease study to collect real world data of patients with severe uncontrolled asthma in Germany.Read full original descriptionShow less
REACT - REAl Care for AsThma A Disease Study to Identify Patients With Severe Uncontrolled Asthma Using EMR Pre-screening and AIRQ® Score Documentation Over 12 Months, Including Patient-documented OCS Use With the AIRQ®-Active Application
This is a multi-center, single-country, single-arm, prospective, disease study to collect real world data of patients with severe uncontrolled asthma in Germany.
Inclusion: ≥18 years of age at the time of consent; Therapy within GINA/NVL steps 4 or 5 and uncontrolled disease in the previous 12 months as per the healthcare provider's assessment; Willing and able to provide written informed consent indicating that they understand the purpose and procedures required for the study and are willing to participate; Able to read, understand, and speak German sufficiently to complete all the questionnaires.
Exclusion: According to the assessment of the study physician: cognitive impairment, psychiatric diseases, severe hearing or vision impairment, insufficient knowledge of the German language, if these factors could influence the ability to provide written consent and correct completion and assessment of the questionnaires; Current participation in an observational study that might, in the investigator's opinion, influence the assessment for the current study, or participation in a randomized clinical trial in the last 30 days.